General Stock Ideas

[gfp927z]

Ombow, >> dragging its heels <<


In addition to funding issues and IPIX's other programs, the neuropathy side effect produced by Brilacidin when given via the IV route (as an antibiotic), and the resulting dosing limitations, may have made IPIX reluctant to make the ABSSSI Phase 3 a high priority. Instead they decided to go with the Oral Mucositis indication, which uses an oral rinse route of administration, so there's much less risk of side effects.

In the earlier ABSSSI trials they had dosed for several days (2 or 3 days as I recall) and had good results, but they couldn't dose much longer due to the side effect. Then they tried a single dose, and even considering Brilacidin's extremely rapid activity against ABSSSI infections (deep skin infections like MRSA), that isn't the ideal way to treat an infection, it's better to dose longer just to be sure.

So they shifted the focus to Oral Mucositis and clinical indications that will benefit from Brilacidin's anti-inflammatory activity. Brilacidin is definitely worth watching, but probably best from the sidelines for now.